CURRICULUM VITAE

November 1, 2018

Name
Roland L Dunbrack, Jr.

Address:
1912 S. 12th St.
Philadelphia, PA 19111

Citizenship:
United States (Born: Waltham, Massachusetts, July 25, 1963)

Education:

Harvard College, Cambridge, MA	A.B., Chemistry *(summa cum laude)*	1981-1985
University of Cambridge, Cambridge, UK		1985-1987
Undergraduate study in biochemistry		
Graduate study in theoretical chemistry		
Harvard University, Cambridge, MA	Ph.D., Biophysics	1987-1993
Supervisors: Professor Martin Karplus, Department of Chemistry		
Professor Jack Strominger, Department of Biochemistry and Molecular Biology		

Postgraduate Training:

Postdoctoral Fellow, Supervisor, University of California, San Francisco, CA	1993-1997
Supervisors: Professor Frederick Cohen, Department of Pharmacology	
Professor Kenneth Dill, Department of Pharmaceutical Chemistry	

Faculty Appointments:

Assistant professor, Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, PA	1997-2003
Associate professor, Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, PA	2003-2011
Professor, Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, PA	2011-date
Adjunct assistant professor of Biochemistry and Molecular Biophysics, University of Pennsylvania School of Medicine, Philadelphia PA	2000-2006
Adjunct associate professor of Biochemistry and Molecular Biophysics, University of Pennsylvania School of Medicine, Philadelphia, PA	2006-2012
Adjunct professor of Biochemistry and Molecular Biophysics, University of Pennsylvania School of Medicine, Philadelphia, PA	2012-date
Adjunct associate professor of Biochemistry, Drexel University College of Medicine, Philadelphia, PA	2004-date
Adjunct professor of Biochemistry, Temple University School of Medicine, Philadelphia, PA	2016-date
Director, Molecular Modeling Facility, Fox Chase Cancer Center	2003-date
Director, Organic Synthesis Facility, Fox Chase Cancer Center	2003-date

Awards and Honors:

John Harvard Scholarship	06/1982, 06/1984
Harvard College Scholarship	06/1983, 06/1985
National Science Foundation Predoctoral Fellowship (1987-1990)	03/1985
Herchel Smith Fellowship, awarded by Harvard College for 1-5 years study at Emmanuel College, University of Cambridge (1985-1987)	03/1985
Phi Beta Kappa, Harvard College, *Alpha* Chapter of Massachusetts	06/1985
National Institute of Health Postdoctoral Fellowship (1993-1996)	08/1993
Senior Research Excellence Award, Temple University School of Medicine	09/2012
Special Contributor Award, Fox Chase Cancer Center	02/2014

Membership in Professional and Scientific Societies:

International Society for Computational Biology (ISCB)

Federal Grant Review Committee Service:

NIH MSF-D Study Section, Regular member		10/2009-10/2011
NIH Study Sections and Site Visit Panels (ad hoc):		
BBCB	Biochemistry and Biophysics B	02/2001
SSS-6 (10)	SBIR proposals	03/2002
BBCA	Biochemistry and Biophysics A	06/2002
MDCN-A (05)	Special Emphasis Panel	12/2003
YZW-A (M1)	NIAMS R03 Panel	03/2004
BBCA	Biochemistry and Biophysics A	06/2004
BCMB-Q (02)	Computational Biochemistry and Biophysics	10/2005
BCMB-G (91)	Special Emphasis Panel	11/2005
BST-L (51)	Software maintenance proposals	01/2006
BCMB-C (40)	P01 review	03/2006
BCMB-Q (90)	Computational Biochemistry and Biophysics	06/2006
BRT-9	K99 proposals	08/2006
BCMB-Q (90)	Computational Biochemistry and Biophysics	10/2006
BCMB-A (92)	Special Emphasis Panel	12/2006
BCMB-N	Computational Biochemistry and Biophysics	02/2007
CBB-3 (HM)	PSI 2 Molecular Modeling proposals	05/2007
BCMB-H (40)	Center for Synchrotron Biosciences, Brookhaven NY	03/2008
MSF-D	Macromolecular Structure and Function D	10/2008
BCMB-P (58)	ARRA proposals	06/2009
BCMB-P (40)	Competitive Revisions of P41 Grants	03/2012
BCMB-H	Special Emphasis Panel	04/2013
MSF-D	Macromolecular Structure and Function D	10/2014
ZGM1 PPBC-0 (GL)	Large-Scale Collaborative Project Awards (R24/U54)	03/2015
CE	Cancer Etiology (mail reviewer)	09/2016
MSF-D	Macromolecular Structure and Function D	06/2017
NSF Site Visit Panel: BioGeometry Project, Duke University, Durham, NC		11/2002
NSF Site Visit Panel: RCSB-Protein Data Bank, New Brunswick, NJ		04/2003
NIH Site Visit Panel: Laboratory of Molecular Biology, NCI, Bethesda, MD		2007, 2009

National and International Committee Service:

Assessor for 6th Meeting on the Critical Assessment of Protein Structure Prediction (CASP6); Assessment of fold-recognition models; Assessment of — 2004

Disorder predictions

External Advisory Board, Seattle Structural Genomics Center for Infectious Diseases (SSGCID), Seattle, WA 2008-date

Advisory Board, RCSB Protein Data Bank, Rutgers Univ., New Brunswick, NJ 2009-date

Assessor for BRCA1/BRCA2 challenge, 3rd Meeting on Critical Assessment of Genome Interpretation, Max Planck Institute, Berlin, Germany 2013

Assessor for 11th Meeting on the Critical Assessment of Protein Structure Prediction (CASP11): (1) Template-based modeling category; (2) Biological inferences from models; (3) Refinement of template-based models category 2014

Editorial Positions:

Editorial Advisory Board, *Protein Science* 2001-2007

Associate Editor, *PLOS Computational Biology* 2008-date

Academic Committees and Activities, Fox Chase Cancer Center:

Biomolecular Structure and Function Faculty Search Committee (Member) 2002-2003

Bioinformatics Facility Oversight Committee (Chair) 2002-2007

Post-doctoral Fellowship Selection Committee (Member) 2003-2008

High-Performance Computing Facility Oversight Committee (Chair) 2006-date

Research Informatics Advisory Committee (Member) 2007-date

Institutional Information Systems Advisory Committee (Member) 2007-date

Molecular Medicine, Faculty Search Committee (Member) 2009-2010

Facility Parent Oversight Committee (Member) 2009-date

2013 Post-doc Day Committee 2012-date

Tenure and Promotions Committee 2015-date

Federal (NIH, DOD, VA) Funding History:

Current

R35 GM122517 (PI: Dunbrack) 04/01/2017 - 03/31/2022

NIH Role: Principal Investigator

Structural bioinformatics of proteins and protein complexes and applications to cancer biology

This MIRA (Maximizing Investigator Research Award) grant funds the entirety of the research in my lab previously funded by NIGMS. The grant is focused on the utilization of structural bioinformatics – the statistical study of experimental structures of proteins and protein complexes – to further our understanding of cancer biology, the effects of mutations discovered in tumor and germline samples, and the development of cancer therapeutics. In particular, we have developed methods for computational antibody design and we are engaged in extensive studies of the structures of protein-protein interactions and protein kinases and their inhibitors.

R01 GM111819 (PI: Dunbrack) 08/01/2015 - 07/31/2017

NIH Role: Principal Investigator

Development of Methods for Antibody Computational Design

The major goals of this project are: 1) To further develop the structural bioinformatics needed to perform accurate antibody design; 2) To refine our existing code for antibody design and optimize sampling and scoring functions via a novel metric for protein design; and 3) To test our antibody design methods experimentally. This grant is being relinquished on 07/31/2017 and will be replaced with R35 MIRA funding from NIGMS.

R01 GM084453 (PI: Dunbrack) 06/01/2013 - 03/31/2018
NIH Role: Principal Investigator

Bayesian Statistics and Algorithms for Homology Modeling

The major goal of this project is to predict the structures of biologically relevant states of proteins and protein complexes and to utilize these in cancer research. The aims of the project are: 1) Non-parametric statistics of protein structure parameters; 2) Comparative modeling of biological assemblies; and 3) The structure of kinase autophosphorylation complexes. This grant will be in a one-year unfunded extension until 03/31/2018 in order to utilize unexpended funds.

R01 GM117437 (PI: Graña, Temple University) 01/01/2016 – 03/31/2017
NIH Role: Co-investigator

Unraveling the complexity of substrate specificity of PP2A/B55A, a major eukaryotic serine/threonine phosphatase

This project is focused on the molecular determinants of substrate specificity of protein phosphatases. Our role in this project is to perform docking calculations of disordered regions of PP2A substrates to the catalytic subunit and the B55a regulatory subunit. This subcontract is being relinquished on 3/31/2017 to be replaced with R35 MIRA funding. The collaboration will continue after this date.

P30 CA006927 (PI: Fisher) 08/12/2016 - 07/31/2021
NIH Role: Facility Director

Comprehensive Cancer Center Program at Fox Chase

The major goal of this Cancer Center Support Grant is to provide partial salary support for professional personnel, including senior and program leadership, administration, planning and evaluation, and developmental funds, as well as support for 4 established peer-reviewed Research Programs, 12 Shared Research Resources and 1 Support Element.

Previous

R01 GM078221 (PI: Gray, JHU) 09/01/2012 - 08/31/2016
NIH Role: Co-PI (5% effort)

Prediction of the Structure of Therapeutic Antibodies with their Antigens

The major goals of this project are to develop new methods for predicting the structures of antibodies and for improved methods of docking antibodies to antigens. My role in this project is to supervise the efforts of graduate student Brian Weitzner in structural bioinformatics analysis of antibody CDRs and the role of beta turns in loop structure prediction.

R03 CA167264 (PI: Egleston) 3/1/2013 - 02/28/2015
NIH Role: Co-PI (5% effort)

Clinical Trials with Exclusions Based on Race, Ethnicity, and English Fluency

The major goals of this project are: 1) To identify and describe characteristics of clinical trials that have explicit inclusion or exclusion criteria related to race or ethnicity; and 2) To identify and describe characteristics of clinical trials that have explicit inclusion or exclusion criteria related to language.

R01 GM073784 (PI: Dunbrack) 03/01/2006 – 02/28/2010
NIH Role: Principal Investigator

Modeling of Protein Complexes and Missense Mutations

The major goals of this project are: 1) A model for missense mutations in protein complexes; 2) Development of database to aid the structure prediction of protein complexes; and 3) Examination of missense mutations associated with cancer

P20 GM076222 (PI: Dunbrack) 04/01/2006 – 03/31/2010
NIH Role: Principal Investigator
New Methods for High-Resolution Comparative Modeling
The major goal of this proposal is to establish a center for high-resolution modeling of protein structures to improve the quality of comparative models both in the >30% sequence identity regime and in the 10-30% sequence identity regime The focus of the center is on the development of powerful new methodology through the integrated efforts of experts in protein structure modeling with computational and mathematical scientists new to protein structure modeling This project includes five subcontracts

R01 HL057299 (PI: Kruger) 01/16/2001 – 11/30/2006
NIH Role: Co-Investigator
Genetic Modulation of CBS to Lower Plasma Homocysteine
The major goals of this project are: 1) Characterization and additional isolation of missense mutations within the regulatory domain of CBS; 2) Determine if mutant CBS enzymes can lower plasma homocysteine levels in vivo using a mouse model; 3) Identify peptamers which can inhibit activity of the regulatory domain of CBS; and 4) Analysis of Adomet binding to both normal and mutant CBS molecules

R01 GM56250 (PI: Roder) 05/01/2002 – 04/30/2006
NIH Role: Co-Investigator
Kinetics of Early Events in Protein Folding
The major goals of this project are: 1) Barriers and intermediates in the folding of protein G; 2) Fluorescence probes to monitor tertiary structure formation during early stages of SNase folding; and 3) Structural characterization of early folding events in SNase by H-D exchange labeling and NMR

U01 AI058269 (PI: Taylor) 09/01/2003 – 02/28/2008
NIH Role: Co-Investigator
Towards a Novel Strategy Against HBV Infection
The major goals of this project are: 1) Establish conditions for the controlled assembly of HDV and evaluate in two different hepatocyte systems the ability to achieve attachment, entry, and the initiation of replication; 2) Use unmodified and/or modified forms of HBV envelope proteins for virion assembly, and identify determinants necessary for attachment, entry, and initiation of HDV replication; and 3) Test small molecules for interference with attachment and entry, usng high throughput screening assays

R21AI063324 (PI: Jaffe) 04/01/2005 – 03/31/2007
NIH Role: Co-Investigator
Hexameric PBGS as a Bioterrorism Defense
The major goals of this project are: 1) Prepare protein structure models of hexameric PBGS proteins for the target species of PBGS that are proposed to freely equilibrate between the hexameric and octameric forms; 2) Use computational methodfs to screen small molecule structural databases for molecules that will selectively bind to the inactive hexameric forms of PBGS from the target organism; and 3) Test the identified candidate molecules, *in vitro* and in an *in vivo* model system, for the ability to inhibit PBGS activity through stabilization of the hexameric form of the protein

Non-Federal, Non-Industry Funding History (ACS, sub-specialty group, other):

No Number (PI: Dunbrack) 1/1/2014 - 12/31/2014
Rosetta Commons Role: Principal Investigator
Development and implementation of statistical scoring functions in Rosetta
The major goals of this project are to develop and test improved statistical scoring functions within Rosetta, including backbone-dependent dihedral and bon angle scoring terms for the backbone and side chains.

69133-01 (PI: Dunbrack) 01/01/2011 – 12/31/2013
Pennsylvania Tobacco Settlement Funds Role: Principal Investigator
Classification and Prediction of Protein-Protein Interactions in Biology and Medicine
The aims of this project are: 1) to improve the assignment of PFAM domains to all proteins of known structure using modern sequence and structure-based methods; 2) to compare and cluster interfaces between domains in all PDB entries; 3) to study the role of specific homodimeric interfaces in activation and inhibition of protein kinases

Keystone Program in Head and Neck Cancer 07/01/2009 –06/30/2011
Fox Chase Cancer Center Role: Co-Principal Investigator
Pilot project on antibody design for head and neck tumor targets
This internal pilot project is a collaboration between Dr Dunbrack's molecular modeling group and investigators in antibody engineering and clinical investigators to design antibodies that target EGFR family proteins

Pilot Project (PI: Roder) 07/01/2008-06/30/2010
Fox Chase Cancer Center Role: Co-Investigator
The role of disordered protein regions in protein function and regulation
This internal pilot project is a collaboration between Dr Dunbrack and Dr Heinrich Roder at Fox Chase to explore the structure, dynamics, and role of the long disordered region in NHERF1 using NMR, electron paramagnetic resonance, fluorescence experiments, and computational modeling

69133-01 (PI: Dunbrack) 01/01/2005 – 6/30/2006
Pennsylvania Tobacco Settlement Funds Role: Principal Investigator
Predicting the effects of disease-associated missense mutations on protein stability and interactions
The goals of this project are to design a statistical model of the effects of missense mutations on protein function, based on changes in protein stability and disruption of protein interactions Structure prediction of complexes and sequence analysis will be used as primary tools

W W Smith Charitable Trust (PI: Dunbrack) 11/01/2000 – 09/30/2002
Role: Principal Investigator
Analysis of Missense Mutations and Polymorphisms in Cancer
The major goal of this project is to examine all identified mutations in several genes associated with cancer and to identify which mutations are most likely to be associated with increased risk of disease using computational methods developed to investigate the evolutionary relationships among related genes, as well as algorithms for predicting the structures of proteins based on their similarity to proteins of known three-dimensional structure The proteins that will be investigated include BRCA1, ATM, APC, the RET proto-oncogene, and TSC2

Bibliography:

Research Publications (peer reviewed):

1. **Dunbrack RL Jr.** Calculation of Franck-Condon factors for undergraduate quantum chemistry. *J Chem Edu* **63**:953-955, 1986.
2. Doyle C, Shin J, **Dunbrack RL Jr.**, Strominger JL. Mutational analysis of the structure and function of the CD4 protein. *Immunol Rev* **109**:17-37, 1989.
3. Shin J, **Dunbrack RL Jr.**, Lee S, Strominger JL. Signals for retention of transmembrane proteins in the ER studied with CD4 truncation mutants. *Proc Natl Acad Sci USA* **88**:1918-1922, 1991.
4. Shin J, **Dunbrack RL Jr.**, Lee S, Strominger JL. Phosphorylation-dependent down modulation of CD4 requires a specific structure within the cytoplasmic domain of CD4. *J Biol Chem* **266**:10658-10665, 1991.
5. **Dunbrack RL Jr.**, Karplus M. A backbone dependent rotamer library for proteins: application to side-chain prediction. *J Mol Biol* **230**:543-571, 1993.
6. Schmidt JM, Brüschweiler R, Ernst RR, **Dunbrack RL Jr.**, Joseph D, Karplus M. Molecular dynamics simulation of the proline conformational equilibrium and dynamics in antamanide using the CHARMM force field. *J Amer Chem Soc* **115**:8747-8756, 1993.
7. **Dunbrack RL Jr.**, Karplus M. Conformational analysis of the backbone-dependent rotamer preferences of protein side chains. *Nat Struct Biol* **1**:334-340, 1994.
8. Fischer S, **Dunbrack RL Jr.**, Karplus M. Cis-trans imide isomerization of the proline dipeptide. *J Amer Chem Soc* **116**:11931-11937, 1994.
9. Byington CL, **Dunbrack RL Jr.**, Cohen FE, Agabian N. Molecular modeling of phosphofructokinase from *Entamoeba histolytica* for the prediction of new antiparasitic agents. *Arch Med Res* **28**:S86-S88, 1997.
10. Bower MJ, Cohen FE, **Dunbrack RL Jr.** Prediction of protein side-chain rotamers from a backbone-dependent rotamer library: a new homology modeling tool. *J Mol Biol* **267**:1268-1282, 1997.
11. **Dunbrack RL Jr.**, Cohen FE. Bayesian statistical analysis of protein side-chain rotamer preferences. *Protein Sci* **6**:1661-1681, 1997.
12. Byington CL, **Dunbrack RL Jr.**, Whitby FG, Cohen FE, Agabian N. *Entamoeba histolytica:* computer-assisted modeling of phosphofructokinase for the prediction of broad-spectrum antiparasitic agents. *Exp Parasitol* **87**:194-202, 1997.
13. Armand P, Kirshenbaum K, Falicov A, **Dunbrack RL Jr.**, Dill, KA, Zuckermann RN, Cohen, FE. Chiral N-substituted glycines can form stable helical conformations. *Fold, Des* **2:**369-375, 1997.
14. MacKerell Jr, AD, Bashford D, Bellott M, **Dunbrack RL Jr.,** Evanseck JD, Field MJ, Fischer S, Gao J, Guo H, Ha S, Joseph-McCarthy D, Kuchnir L, Kuczera K, Lau FTK, Mattos C, Michnick S, Ngo T, Nguyen DT, Prodhom B, Reiher WE III, Roux B, Schlenkrich M, Smith JC, Stote R, Straub J, Watanabe M, Wiorkiewicz-Kuczera J, Yin D, Karplus M. All-atom empirical potential for molecular modeling and dynamics studies of proteins. *J Phys Chem B* **102**:3586-3616, 1998.
15. Williams M, Lyu MS, Yang YL, Lin EP, **Dunbrack RL Jr.**, Birren B, Cunningham J, Hunter K. Ier5, a novel member of the slow-kinetics immediate-early genes. *Genomics* **55**:327-334, 1999.
16. Moraleda G, Seeholzer S, Bichko V, **Dunbrack RL Jr.**, Otto J, Taylor J. Unique properties of the large antigen of hepatitis delta virus. *J Virol* **73**:7147-7152, 1999.

17. **Dunbrack RL Jr.** Comparative modeling of CASP3 targets using PSI-BLAST and SCWRL. *Proteins: Structure, Function, Genetics* **3**:81-87, 1999.
18. Zhang Y-Z, Gould KL, **Dunbrack RL Jr.**, Cheng H, Roder H, Golemis EA. The evolutionarily conserved Dim1 protein defines a novel branch of the thioredoxin fold superfamily adapted to cell cycle regulation. *Physiol Genomics* **1**:109-118, 1999.
19. Jaffe EK, Volin M, Bronson-Mullins CR, **Dunbrack RL Jr.**, Kervinen J, Martins J, Quinlan JF, Jr, Sazinsky MH, Steinhouse EM, Yeung AT. An artificial gene for human porphobilinogen synthase allows comparison of an allelic variation implicated in susceptibility to lead poisoning. *J Biol Chem* **275**:2619-2626, 2000.
20. Sauder JM, Arthur JW, **Dunbrack RL Jr.** Large-scale comparison of protein sequence alignment algorithms with structure alignments. *Proteins: Structure, Function, Genetics* **40**:6-22, 2000.
21. Sauder JM, **Dunbrack RL Jr.** Genomic fold assignment and rational modeling of proteins of biological interest. *Intelligent Systems Mol Biol (ISMB)* **8:**296-306, 2000.
22. Sauder JM, Arthur JW, **Dunbrack RL Jr.** Modeling of substrate specificity of the Alzheimer's disease amyloid precursor protein β-secretase. *J Mol Biol* **300**:241-248, 2000.
23. Kervinen J, **Dunbrack RL Jr.**, Litwin S, Martins J, Scarrow RC, Volin M, Yeung AT, Yoon E, Jaffe EK. Porphobilinogen synthase from pea: expression from an artificial gene, kinetic characterization, and novel implications for subunit interactions. *Biochemistry* **39**:9018-9029, 2000.
24. Salicioni AM, Xi M, Vanderweer L, Balsara B, Testa J, **Dunbrack RL Jr.**, Godwin, A. Identification and structural analysis of human RBM8A and RBM8B: two highly conserved RNA-binding motif proteins that interact with OVCA1, a candidate tumor suppressor. *Genomics* **69**:54-62, 2000.
25. Berger MA, Carleton M, Rhodes M, Sauder JM, Trop S, **Dunbrack RL Jr.**, Hugo P, Wiest DW. Identification of a novel pre-TCR isoform in which the accessibility of the TCRβ subunit is determined by occupancy of the 'missing' V domain of pre-tα. *Int Immunol* **12**:1579-1591, 2000.
26. Yi J, Arthur JW, **Dunbrack RL Jr.**, Skalka AM. An inhibitory monoclonal antibody binds at the turn of the helix-turn-helix motif in the N-terminal domain of HIV-1 integrase. *J Biol Chem* **275**:38739-38748, 2000.
27. Jaffe EK, Martins J, Li J, Kervinen J, **Dunbrack RL Jr.** The molecular mechanism of lead inhibition of human porphobilinogen synthase. *J Biol Chem* **276**:1531-1537, 2001.
28. Shan X, **Dunbrack RL Jr.**, Christopher SA, Kruger WD. Mutations in the regulatory domain of cystathionine β-synthase can functionally suppress patient-derived mutations in *cis. Hum Mol Genet* **10**:635-643, 2001.
29. Fischer D, Elofsson A, Rychlewski L, Pazos F, Valencia A, Rost B, Ortiz AR, **Dunbrack RL Jr.** CAFASP2: the second critical assessment of fully automated structure prediction methods. *Proteins: Structure, Function, Genetics* **5**:171-183, 2001.
30. Prowse AH, Vanderveer L, Milling SWF, **Dunbrack RL Jr.**, Xu X-X, Godwin AK. *OVCA2* is downregulated and degraded during retinoid-induced apoptosis. *Int J Cancer* **99**:185-192, 2002.
31. Kahsay RY, Wang G, Dongre N, Gao G, **Dunbrack RL Jr.** CASA: a server for the critical assessment of protein sequence alignment accuracy. *Bioinformatics* **18**:496-497, 2002.
32. Hang H, Zhang Y, **Dunbrack RL Jr.**, Wang C, Lieberman HB. Identification and characterization of a paralog of human cell cycle checkpoint gene HUS1. *Genomics* **79**:487-492, 2002.
33. Grant JD, **Dunbrack RL Jr.**, Manion FJ, Ochs MF. BeoBLAST: distributed BLAST and PSI-BLAST on a Beowulf cluster. *Bioinformatics* **18**:765-766, 2002.

34. Cheng JD, **Dunbrack RL Jr.**, Valianou M, Rogatko A, Alpaugh RK, Weiner LM. Promotion of tumor growth by murine FAP, a serine protease, in an animal model. *Cancer Res* **62**:4767-4772, 2002.
35. Yi J, Cheng H, Andrake MD, **Dunbrack RL Jr.**, Roder H, Skalka AM. Mapping the epitope of an inhibitory monoclonal antibody to the C-terminal DNA-binding domain of HIV-1 integrase. *J Biol Chem* **277**:12164-12174, 2002.
36. Fischer D, Rychlewski L, **Dunbrack RL Jr.**, Ortiz AR, Elofsson A. CAFASP3: the third critical assessment of fully automated structure prediction methods. *Proteins* **53**:503-516, 2003.
37. Canutescu AA, Shelenkov AA, **Dunbrack RL Jr.** A graph-theory algorithm for rapid protein side-chain prediction. *Protein Sci* **12**:2001-2014, 2003.
38. Wang G, **Dunbrack RL Jr.** PISCES: a protein sequence culling server. *Bioinformatics* **19**:1589-1591, 2003.
39. Kundrat L, Martins J, Stith L, **Dunbrack RL Jr.**, Jaffe EK. A structural basis for half-of-the-sites metal binding revealed in D melanogaster porphobilinogen synthase. *J Biol Chem* **278**:31325-31330, 2003.
40. Canutescu AA, **Dunbrack RL Jr.** Cyclic coordinate descent: A robotics algorithm for protein loop closure. *Protein Sci* **12**:963-972, 2003.
41. Wang G, **Dunbrack RL Jr.** Scoring profile-to-profile sequence alignments. *Protein Sci* **13**:1612-1626, 2004.
42. Zhang R, Poustovoitov MV, Ye X, Santos HA, Chen W, Duganzo SM, Erzberger JP, Serebriiskii JG, Canutescu AA, **Dunbrack RL Jr.** Pehrson JR, Berger JM, Kaufman PD, Adams PD. Formation of MacroH2A-containing senescence-associated heterochromatin foci and senescence driven by ASFIa and HIRA. *Dev Cell* **8**:19-30, 2005.
43. Canutescu AA, **Dunbrack RL Jr.** MollDE: a homology modeling framework you can click with. *Bioinformatics* **21**:2914-2916, 2005.
44. Wang G, **Dunbrack RL Jr.** PISCES: recent improvements to a PDB sequence culling server. *Nucleic Acids Res* **33**:W94-W98, 2005.
45. Kahsay RY, Wang G, Gao G, Liao L, **Dunbrack RL Jr.** Quasi-consensus based comparison of profile hidden Markov models for protein sequences. *Bioinformatics* **21**:2287-2293, 2005.
46. Tarn C, Merkel E, Canutescu A, Shen W, Skorobogatko Y, Heslin M, Eisenberg B, Birbe R, Patchefsky A, **Dunbrack RL Jr.**, Arnoletti J, von Mehren M, Godwin AK. Analysis of KIT mutations in sporadic and familial GIST: Therapeutic implications using protein modeling. *Clin Canc Res* **11**:3668-3677, 2005.
47. Jin Y, **Dunbrack RL Jr.** Assessment of disorder predictions in CASP6. *Proteins* **7**:167-175, 2005.
48. Wang G, Jin Y, **Dunbrack RL Jr.** Assessment of fold recognition predictions in CASP6. *Proteins* **7**:46-66, 2005.
49. Tress M, Tai CH, Wang G, Ezkurdia I, Lopez G, Valencia A, Lee B, **Dunbrack RL Jr.** Domain definition and target classification for CASP6. *Proteins* **7**:8-18, 2005.
50. Krasley E, Cooper KF, Mallory MJ, **Dunbrack RL**, Strich R. Regulation of the oxidative stress response through Slt2p-dependent destruction of cyclin C in *Saccharomyces cerevisiae. Genetics* **172**:1477-1486, 2006 .
51. Berman HM, Burley SK, Chiu W, Sali A, Adzhubei A, Bourne PE, Bryant SH, **Dunbrack RL Jr.**, Fidelis K, Frank J, Godzik A, Henrick K, Joachimiak A, Heymann B, Jones D, Markley JL, Moult J, Montelione GT, Orengo C, Rossmann MG, Rost B, Saibil H, Schwede T, Standley DM, Westbrook JD. Outcome of a workshop on archiving structural models of

biological macromolecules. *Structure* **14**:1211-7, 2006.

52. Xu Q, Canutescu A, Obradvic Z, **Dunbrack RL Jr.** ProtBuD: a database of biological unit structures of protein families and superfamilies. *Bioinformatics* **22**:2876-2882, 2006.
53. Tang Y, Poustovoitov MV, Zhao K, Garfinkel M, Canutescu A, **Dunbrack R**, Adams PD, Marmorstein R. Structure of a human ASF1a-HIRA complex and insights into specificity of histone chaperone complex assembly. *Nat Struct Mol Biol* **13**:921-9, 2006.
54. Shapovalov MV, **Dunbrack RL Jr.** Statistical and conformational analysis of the electron density of protein side chains. *Proteins* **66**:279-303, 2007.
55. Gudima S, Meier A, **Dunbrack R**, Taylor J, Bruss V. Two potentially important elements of the hepatitis B virus large envelope protein are dispensable for the infectivity of hepatitis delta virus. *J Virol* **81**:4343-4347, 2007.
56. Shapovalov MV, Canutescu AA, **Dunbrack RL Jr.** BioDownloader: Bioinformatics downloads and updates in a few clicks. *Bioinformatics* **23**:1437-1439, 2007.
57. Karplus PA, Shapovalov MV, **Dunbrack RL Jr.**, Berkholz DS. A forward-looking suggestion for resolving the stereochemical restraints debate: ideal geometry functions. *Acta Crystallogr D Biol Crystallogr* **64**:335-336, 2008.
58. Pietsch EC, Perchiniak E, Canutescu AA, Wang G, **Dunbrack RL**, Murphy ME. Oligomerization of BAK by p53 utilizes conserved residues of the p53 DNA binding domain. *J Biol Chem* **283**:21294-21304, 2008. PMCID: PMC2475706.
59. Xu Q, Canutescu AA, Wang G, Shapovalov M, Obradovic Z, **Dunbrack RL Jr.** Statistical analysis of interface similarity in crystals of homologous proteins. *J Mol Biol* **381**:487-507, 2008. PMCID: PMC2573399.
60. Wang Q, **Dunbrack RL.** An integrated database for complex protein structure. Modeling Proceedings, IEEE Int Conf Bioinformatics Biomed) **2008:**33-40, 2008. PMCID: PMC3000042.
61. Wang Q, Canutescu AA, **Dunbrack RL Jr.** SCWRL and MollDE: computer programs for side-chain conformation prediction and homology modeling. *Nat Protoc* **3**:1832-1847, 2008 PMCID: PMC2682191.
62. Weitzner B, Meehan T, Xu Q, **Dunbrack RL Jr.** An unusually small dimer interface is observed in all available crystal structures of cytosolic sulfotransferases. *Proteins* **75**:289-295, 2009. PMCID: PMC2728805.
63. Schwede T, Sali A, Honig B, Levitt M, Berman HM, Jones D, Brenner SE, Burley SK, Das R, Dokholyan NV, **Dunbrack RL Jr.**, Fidelis K, Fiser A, Godzik A, Huang YJ, Humblet C, Jacobson MP, Joachimiak A, Krystek SR, Jr, Kortemme T, Kryshtafovych A, Montelione GT, Moult J, Murray D, Sanchez R, Sosnick TR, Standley DM, Stouch T, Vajda S, Vasquez M, Westbrook JD, Wilson IA. Outcome of a workshop on applications of protein models in biomedical research. *Structure* **17**:151-159, 2009. PMCID: PMC2739730.
64. Krivov GG, Shapovalov MV, **Dunbrack RL Jr.** Improved prediction of protein side-chain conformations with SCWRL4. *Proteins* **77**:778-795, 2009. PMCID: PMC2885146.
65. Berkholz DS, Shapovalov MV, **Dunbrack RL Jr.,** Karplus PA. Conformation dependence of backbone geometry in proteins. *Structure* **17**:1316-1325, 2009. PMCID: PMC2810841.
66. Bourne PE, Beran B, Bi C, Bluhm W, **Dunbrack R,** Prlic A, Quinn G, Rose P, Shah R, Tao W, Weitzner B, Yukich B. Will widgets and semantic tagging change computational biology? *PLoS Comput Biol* **6**:e1000673 2010. PMCID: PMC2829027.
67. Wei Q, Wang L, Wang Q, Kruger WD, **Dunbrack RL Jr.** Testing computational prediction of missense mutation phenotypes: functional characterization of 204 mutations of human cystathionine beta synthase. *Proteins* **78**:2058-74, 2010. PMCID: PMC3040297.

68. Egleston BL, **Dunbrack RL Jr.,** Hall MJ. Clinical trials that explicity exclude gay and lesbian patients. *N Engl J Med* **362**:1054-5, 2010. PMCID: PMC2875120.

69. Tong X, Zitserman D, Serebriskii I, Andrake M, **Dunbrack R,** Roegiers F. Numb independently antagonizes Sanpodo membrane targeting and Notch signaling in Drosophila sensory organ precursor cells. *Mol Biol Cell* **21**:802-10, 2010 PMCID: PMC2828966.

70. Li C, Andrake M, **Dunbrack R**, Enders GH. A bifunctional regulatory element in human somatic Wee1 mediates cyclin A/Cdk2 binding and Crm1-dependent nuclear export. *Mol Cell Biol* **30**:116-30, 2010. PMCID: PMC2798281.

71. Shandler SJ, Shapovalov MV, **Dunbrack RL Jr.,** DeGrado WF. Development of a rotamer library for use in beta-peptide foldamer computational design. J Am Chem Soc **132**:7312-20, 2010. PMCID: PMC3079439.

72. Xue B, **Dunbrack RL**, Williams RW, Dunker AK, Uversky VN. PONDR-FIT: a meta-predictor of intrinsically disordered amino acids. *Biochim Biophys Acta* **1804**:996-1010, 2010. PMCID: PMC2882806.

73. Plotnikova OV, Pugacheva EN, **Dunbrack RL**, Golemis EA. Rapid calcium-dependent activation of Aurora-A kinase. *Nat Commun* **1**:64 2010. PMCID: PMC2963827.

74. Doulias PT, Greene JL, Greco TM, Tenopoulou M, Seeholzer SH, **Dunbrack RL**, Ischiropoulos H. Structural profiling of endogenous S-nitrosocysteine residues reveals unique features that accommodate diverse mechanisms for protein S-nitrosylation. *Proc Natl Acad Sci U S A* **107**:16958-63, 2010. PMCID: PMC2947911.

75. Ting D, Wang G, Shapovalov MV, Mitra R, Jordan MI, **Dunbrack RL Jr.** Neighbor-dependent Ramachandran probability distributions of amino acids developed from a hierarchical Dirichlet process model. *PLOS Comp Biol* **6**:e1000763, 2010. PCMID: PMC2861699.

76. Hayik SA, **Dunbrack R**, Merz KM. A mixed QM/MM scoring function to predict protein-ligand binding affinity. *J Chem Theory Comput* **6**:3079-3091, 2010. PMCID: PMC3017370.

77. Xu Q, **Dunbrack RL Jr.** ProtCid: the Protein Common Interface Database. *Nucleic Acids Res* **39**:D761-770, 2011. PMCID: PMC3013667.

78. North B, Lehmann A, **Dunbrack RL Jr.** A new clustering of antibody CDR loop conformations. *J Molec Biol* **406**:228-256, 2011. PMCID: PMC3065967.

79. Shapovalov MV, **Dunbrack RL Jr.** A smoothed backbone-dependent rotamer library for proteins derived from adaptive kernel density estimates and regressions. *Structure (Cell Press)* **19**:844-858, 2011. PMCID: PMC3118414.

80. Beglov D, Hall DR, Brenke R, Shapovalov MV, **Dunbrack RL Jr.**, Kozakov D, Vajda S. Minimal ensembles of side chain conformers for modeling protein-protein interactions. *Proteins* **80**:591-601, 2011. PMCID: PMC3297704.

81. Berkholz DS, Driggers CM, Shapovalov MV, **Dunbrack RL Jr.**, Karplus PA. Nonplanar peptide bonds in proteins are common and conserved but not biased toward active sites. *Proc Natl Acad Sci USA* **109**:449-453, 2012. PMCID: PMC3258596.

82. Krieger E, **Dunbrack RL Jr.**, Hooft RW, Krieger B. Assignment of protonation states in proteins and ligands: combining pKa prediction with hydrogen bonding network optimization. *Methods Mol. Biol.* **819**:405-421, 2012.

83. Roberts JL, Buckley RH, Luo B, Pei J, Lapidus A, Peri S, Wei Q, Shin J, Parrott RE, **Dunbrack RL Jr.**, Testa JR, Zhong XP, Wiest DL. CD45-deficient severe combined immunodeficiency caused by uniparental disomy. *Proc Natl Acad Sci USA* **109**:10456-10461, 2012. PMCID: PMC3387083.

84. Xu Q, **Dunbrack RL Jr.** Assignment of protein sequences to existing domain and family classification systems: Pfam and the PDB. *Bioinformatics* **28**:2763-2772, 2012. PMCID: PMC3476341.

85. Wei Q, Xu Q, **Dunbrack RL Jr.** Prediction of phenotypes of missense mutations in human proteins from the structures of biological assemblies. *Proteins* **81**:199-213, 2013. PMCID: PMC3552143.

86. Bojja RS, Andrake MD, Merkel G, Weigand S, **Dunbrack RL Jr.**, Skalka AM. Architecture and assembly of HIV integrase multimers in the absence of DNA substrates. *J Biol Chem* **288**:7373-7386, 2013. PMCID: PMC3591645.

87. Balaburski GM, Leu JI, Beeharry N, Hayik, S, Andrake MD, Zhang G, Herlyn M, Villanueva J, **Dunbrack RL Jr.**, Yen T, George DL, Murphy ME. A modified HSP70 inhibitor shows broad activity as an anticancer agent. *Mol Cancer Res* **11**:219-229, 2013. PMCID: PMC3606282

88. Jaffe EK, Stith L, Lawrence SH, Andrake M, **Dunbrack RL Jr.** A new model for allosteric regulation of phenylalanine hydroxylase: Implications for disease and therapeutics. *Arch Biochem Biophys* **530**:73-82, 2013. PMCID: PMC3580015.

89. Anastassiadis T, Duong-Ly KC, Deacon SW, Lafontant A, Ma H, Devarajan K, **Dunbrack RL Jr.,** Wu J, Peterson JR. A highly selective dual insulin receptor (IR)/insulin-like growth factor 1 receptor (IGF-1R) inhibitor derived from an ERK inhibitor. *J Biol Chem* **288**:28068-28077, 2013. PMCID: PMC3784719.

90. Wei Q, **Dunbrack RL Jr.** The role of balanced training and testing data sets for binary classifiers in bioinformatics. *PLOS ONE* **8**:e67863, 2013. PMCID: PMC3706434.

91. Adolf-Bryfogle J, **Dunbrack RL Jr.** The PyRosetta Toolkit: a graphical user interface for the Rosetta software suite. PLOS ONE **8**:e66856, 2013. PMCID: PMC3706480.

92. Slusky JS, **Dunbrack RL Jr.** Charge asymmetry in the proteins of the outer membrane. *Bioinformatics* **29**:2122-8, 2013. PMCID: PMC3740626

93. Law MJ, Mallory MJ, **Dunbrack RL Jr.,** Strich R. Acetylation of the transcriptional repressor Ume6p allows efficient promoter release and timely induction of the meiotic transient transcription program in yeast. *Mol Cell Biol* **34**:631-42, 2014. PMCID: PMC3911482.

94. Shapovalov MV, Wang Q, Xu Q, Andrake MD, **Dunbrack RL Jr.** BioAssemblyModeler (BAM): User-friendly homology modeling of protein homo- and heterooligomers. *PLOS ONE* **9**:e98309, 2014. PMCID: PMC4055448.

95. Adolf-Bryfogle J, Xu Q, North B, Lehmann A, **Dunbrack RL Jr.** PyIgClassify: A database of antibody CDR structural classifications. *Nucleic Acids Research (database issue)* **43**:D432-438, 2015. DOI: 10.1093/nar/gku1106; PMCID: PMC4383924.

96. Vijayan RS, He P, Modi V, Duong-Ly KC, Ma H, Peterson JR, **Dunbrack RL Jr.**, Levy RM. Conformational analysis of the DFG-out kinase motif and biochemical profiling of structurally validated Type II inhibitors. *J Med Chem* **58**:477-479, 2015. PMCID: PMC4326797.

97. Weitzner BD, **Dunbrack RL Jr.**,* Gray JJ*. The origin of CDR H3 structural diversity. *Structure* **23**:302-311, 2015. *Corresponding authors. PMCID: PMC4318709.

98. Lehmann AK, Wixted JHF, Shapovalov MV, Roder H, **Dunbrack RL Jr.**,* Robinson MK.* Stability engineering of anti-EGFR scFv antibodies by rational design of a l-to-k swap of the VL framework using a structure-guided approach. *mAbs* **7**:1058-1071, 2015. DOI:10.1080/19420862.2015.1088618; PMCID: PMC4966335.

99. Xu Q, Malecka KL, Fink L, Jordan JJ, Duffy E, Kolander S, Peterson J, **Dunbrack RL Jr.**

Three-dimensional structures of autophosphorylation complexes in crystals of protein kinases. *Science Signaling* **8**:rs13, 2015. DOI:10.1126/scisignal.aaa6711; PMCID: PMC4766099.

100. Shih J, Bashir B, Gustafson KS, Andrake M, **Dunbrack RL Jr.**, Goldstein LJ, Boumber Y. Cancer Signature Investigation: ERBB2 (HER2)-Activating Mutation and Amplification-Positive Breast Carcinoma Mimicking Lung Primary. *J Natl Compr Canc Netw*. **13**:947-52, 2015. PMCID: PMC4763101.
101. Plimack ER, **Dunbrack RL Jr.**, Brennan TA, Andrake MD, Zhou Y, Serebriiskii IG, Slifker M, Alpaugh K, Dulaimi E, Palma N, Hoffman-Censits J, Bilusic M, Wong YN, Kutikov A, Viterbo R, Greenberg RE, Chen DY, Lallas CD, Trabulsi EJ, Yelensky R, McConkey DJ, Miller VA, Golemis EA, Ross EA. Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer. *Eur Urol.* **68**:959-967, 2015. DOI: 10.1016/k.eururo.2015.07.009; PMCID: PMC4764095.
102. Egleston BL, Pedraza O, Wong YN, **Dunbrack** RL Jr, Griffin CL, Ross EA, Beck JR. Characteristics of clinical trials that require participants to be fluent in English. *Clin Trials* 12:618-626, 2015. PMCID: PMC4643363.
103. Nicolas E, Arora S, Zhou Y, Serebriiskii IG, Andrake MD, Handorf ED, Bodian DL, Vockley JG, Dunbrack RL, Ross EA, Egleston BL, Hall MJ, Golemis EA, Giri VN, Daly MB. Systematic evaluation of underlying defects in DNA repair as an approach to case-only assessment of familial prostate cancer. *Oncotarget* 6:39614-39633, 2015. DOI: 10.18632/oncotarget.5554; PMCID: PMC4741850.
104. Kinch LN, Li W, Schaeffer RD, Dunbrack RL, Monastyrskyy B, Kryshtafovych A, Grishin NV. CASP11 target classification. *Proteins* **84 Suppl. 1**: 20-33, 2016. DOI: 10.1002/prot.24982; PMCID: PMC4940306.
105. Huwe PJ, Xu Q, Shapovalov MV, Modi V Andrake MD, Dunbrack RL. Biological function derived from predicted structures in CASP11. *Proteins* **84 Suppl. 1**:370-391, 2016. DOI: 10.1002/prot.24997; PMCID: PMC4963311.
106. Modi V, Xu Q, Adhikari S, **Dunbrack** RL. Assessment of template-based modeling of protein structure in CASP11. *Proteins* **84 Suppl. 1**:200-220, 2016. DOI: 10.1002/prot.25049; PMCID: PMC5030193.
107. Modi V, **Dunbrack** RL. Assessment of refinement of template-based models in CASP11. *Proteins* **84 Suppl. 1**:260-281, 2016. DOI: 10.1002/prot.25048; PMCID: PMC5030126.
108. Weitzner BD, Jeliazkov JR, Lyskov S, Marze N, Kuroda D, Frick R, Adolf-Bryfogle J, Biswas N, **Dunbrack** RL Jr, Gray JJ. Modeling and docking of antibodies with Rosetta. *Nature Protocols* **12**:401-416, 2017. PMCID: PMC5739521.
109. Xu Q, Tang Q, Katsonis P, Lichtarge O, Jones D, Babbi G, Martelli PL, Casadio R, Lee GR, Seok C, Fenton A, **Dunbrack RL, Jr.** Benchmarking predictions of allostery in liver pyruvate kinase in CAGI4. *Human Mutation* **38**:1123-1131, 2017. PMCID: PMC5561472.
110. Carraro M, Minervini G, Giollo M, Bromberg Y, Capriotti E, Casadio R, Dunbrack R, Elefanti L, Fariselli P, Ferrari C, Gough J, Katsonis P, Leonardi E, Lichtarge O, Menin C, Martelli PL, Niroula A, Pal LR, Repo S, Scaini MC, Vihinen M, Wei Q, Xu Q, Yang Y, Yin Y, Zaucha J, Zhao H, Zhou Y, Brenner SE, Moult J, Tosatto SCE. Performance of in silico tools for the evaluation of p16INK4a (CDKN2A) variants in CAGI. *Human Mutation* **38**:1042-1050, 2017. doi: 10.1002/humu.23235. PMCID: PMC5561474.
111. Arora S, Huwe PJ, Sikder R, Shah M, Browne AJ, Lesh R, Nicolas E, Deshpande S, Hall MJ, **Dunbrack RL Jr,** Golemis EA. Functional analysis of rare variants in mismatch repair proteins augments results from computation-based predictive methods. *Cancer Biol.*

Therapy **18**:519-533, 2017. DOI: 10.1080/15384047.2017.1326439. PMCID: PMC5639829.

112. Alford RF, Leaver-Fay A, Jeliazkov JR, O'Meara MJ, DiMaio FP, Park H, Shapovalov MV, Renfrew PD, Mulligan VK, Kappel K, Labonte JW, Pacella MS, Bonneau R, Bradley P, **Dunbrack RL Jr,** Das R, Baker D, Kuhlman B, Kortemme T, Gray JJ. The Rosetta all-atom energy function for macromolecular modeling and design. *J Chem Theory Comput.* May 12. doi: 10.1021/acs.jctc.7b00125, 2017. PMID: 28430426. PMCID: PMC5717763.
113. Deihimi S, Lev A, Slifker M, Shagisultanova E, Xu Q, Jung K, Vijayvergia N, Ross EA, Xiu J, Swensen J, Gatalica Z, Andrake M, **Dunbrack RL**, El-Deiry WS. BRCA2, EGFR, and NTRK mutations in mismatch repair-deficient colorectal cancers with MSH2 or MLH1 mutations. *Oncotarget* **8**:39945-39962, 2017. doi: 10.18632/oncotarget.18098, PMCID: PMC5522275.
114. Matthew EM, Yang Z, Peri S, Andrake M, **Dunbrack R**, Ross E, El-Deiry WS. Plk2 Loss Commonly Occurs in Colorectal Carcinomas but not Adenomas: Relationship to mTOR Signaling. *Neoplasia* **20**:244-255, 2018. doi: 10.1016/j.neo.2018.01.004.
115. Fahl SP, Coffey F, Kain L, Zarin P, **Dunbrack RL Jr.**, Teyton L, Zúñiga-Pflücker JC, Kappes DJ, Wiest DL. Role of a selecting ligand in shaping the murine γδ-TCR repertoire. *Proc Natl Acad Sci U S A.* 115:1889-1894, 2018. doi: 10.1073/pnas.1718328115.
116. Adolf-Bryfogle J, Kalyuzhniy O, Kubitz M, Weitzner BD, Hu X, Adachi Y, Schief WR, **Dunbrack RL Jr.** RosettaAntibodyDesign (RAbD): A general framework for computational antibody design. *PLOS Comput Biol.* **14**:e1006112, 2018. doi: 10.1371/journal.pcbi.1006112. PMCID: PMC5942852.
117. Gupta S, Kelow S, Wang L, Andrake M, **Dunbrack RL Jr**, Kruger WD. Mouse modeling and structural analysis of the p.G307S mutation in human cystathionine β-synthase (CBS) reveal effects on CBS activity but not stability. *J Biol Chem.* **293**:13921-13931, 2018. doi: 10.1074/jbc.RA118.002164. PMCID: PMC6130948
118. Rudolph MJ, Vance DJ, Kelow S, Angalakurthi SK, Nguyen S, Davis SA, Rong Y, Middaugh CR, Weis DD, **Dunbrack** R Jr, Karanicolas J, Mantis NJ. Contribution of an unusual CDR2 element of a single domain antibody in ricin toxin binding affinity and neutralizing activity. *Protein Eng Des Sel.* in press, 2018. doi: 10.1093/protein/gzy022.

Editorials, Reviews, and Chapters:

1. **Dunbrack RL Jr.**, Gerloff DL, Bower M, Chen X, Lichtarge O, Cohen FE. Meeting review: The second meeting on the critical assessment of techniques for protein structure prediction (CASP2), Asilomar, CA, December 13-16, 1996. *Fold Des* **2**:R27-R42, 1997.
2. **Dunbrack RL Jr.** Bayesian statistics in molecular and structural biology In: Computational Biochemistry and Biophysics (MacKerell A, Watanabe M, Roux B, Becker OM, eds.), pp. 313-349, Marcel Dekker, Inc, New Your, 2000.
3. **Dunbrack RL Jr.**, Dunker K, Godzik A. Protein structure prediction in biology and medicine. *Pac Symp Biocomput* **2000**:93-4, 2000.
4. **Dunbrack RL Jr.** Homology modeling in biology and medicine In: Bioinformatics: From Genomes to Drugs (Lengauer, T, ed), pp. 145-235, Wiley VCH Press, Berlin, 2001.
5. Bove B, Sauder JM, **Dunbrack RL Jr.**, Godwin, AK. BRCA1, BRCA2, and hereditary breast cancer In: Breast Cancer: Prognosis-Treatment-Prevention (Pasqualini, J, ed) pp. 555-624, Marcel Dekker, New York, 2002.

6. **Dunbrack RL Jr.** Rotamer libraries in the 21st century. *Curr Opin Struct Biol* **12**:431-440, 2002.

7. **Dunbrack RL Jr.** Book review: A scoundrel's refuge: Structural Bioinformatics, P E Bourne, H Weissig, eds, *Nature Struct Biol* **10**:590, 2003.

8. **Dunbrack RL Jr.** Homology modeling and structural genomics In: Structural Proteomics (Edwards, Al, Sundstrom, M, Norin, M, eds), pp. 109-136 Marcel Dekker, 2005.

9. **Dunbrack RL Jr.** Sequence comparison and protein structure prediction. *Curr Opin Struct Biol* **16**:374-384, 2006

10. **Dunbrack RL Jr.** Homology modeling in biology and medicine In: Bioinformatics: From Genomes to Therapies, Volume 1 (Lengauer, T, ed.), pp. 297-350, Wiley VCH Press, Berlin, 2007.

11. Mehra R, Serebriiskii IG, **Dunbrack RL Jr.**, Robinson MK, Burtness B, Golemis EA. Protein-intrinsic and signaling network-based sources of resistance to EGFR- and ErbB family-targeted therapies in head and neck cancer. *Drug Resist Updat* **14**:260-279, 2011. PMCID: PMC3195944.

12. Nikonova AS, Astsaturov I, Serebriiskii IG, **Dunbrack RL Jr.**, Golemis EA. Aurora-A (AURKA) kinase in normal and pathological cell growth. *Cell Molec Life Sciences* **70:**661-687, 2013. PMCID: PMC3607959.

13. Shapovalov MV, **Dunbrack RL Jr.** Non-Parametric Statistical Analysis of the Ramachandran Map. In: Biomolecular Forms and Functions: 50 Years of the Ramachandran Map (Bansal, M, Srinivasan, N, eds.). World Scientific. Singapore, 2013. PDF: https://www.researchgate.net/publication/300105131_Non-parametric_statistical_analysis_of_the_Ramachandran_map

14. Shagisultanova E, **Dunbrack RL Jr.**, Golemis EA. Issues in interpreting in vivo activity of Aurora A. *Expert Opin Ther Targets* **19**:187-200, 2015. PMCID: PMC4294965.